Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1

Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'. In a regulatory filing, Zydus Cadila said "it has received permission to initiate the phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. NLRP3 inflammasomes are involved in the inflammation process".

from IndiaTV India: Google News Feed https://ift.tt/2VO5q4B

Get Breaking news, Live news, and latest news from India and around the world on INDILIVENEWS.com, which are in the interest of nation and humanity. Like us on Facebook or Follow us on Twitter and Reddit for the latest news blog and live news update